by Plus Therapeutics | Nov 14, 2025 | GBM
Plus Therapeutics is proud to share that the ReSPECT-GBM clinical trial is now a featured study on the American Brain Tumor Association (ABTA) website. This recognition highlights the growing visibility and clinical importance of our work to develop new therapeutic...
by Plus Therapeutics | Nov 10, 2025 | LM
Each November, Lung Cancer Awareness Month serves as a national reminder of the impact lung cancer has on patients, families, and communities. It is also a time to highlight the growing need for better diagnostic and treatment options—especially for patients facing...
by Plus Therapeutics | Nov 6, 2025 | LM
Plus Therapeutics is pleased to announce its participation at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting and the Melanoma Research Foundation (MRF) Brain Metastases Summit 4.0, taking place on November 9, 2025, in Alexandria, VA. This annual...
by Plus Therapeutics | Nov 5, 2025 | Uncategorized
Plus Therapeutics President & CEO, Marc Hedrick, MD, recently joined Nicole R. on the pharmaphorum podcast for an in-depth conversation about how the Company is developing next-generation radiotherapeutics designed to address some of the most difficult-to-treat...
by Plus Therapeutics | Nov 3, 2025 | Uncategorized
Plus Therapeutics (NASDAQ: PSTV) was recently highlighted in an article by Mary Caffrey in The American Journal of Managed Care (AJMC) — one of the leading peer-reviewed journals covering the intersection of clinical innovation, policy, and patient access. The...
Recent Comments